{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T02:14:09Z","timestamp":1792030449482,"version":"4.4.0"},"reference-count":125,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["bjanaesthesia.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["British Journal of Anaesthesia"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.bja.2026.02.031","type":"journal-article","created":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T05:12:50Z","timestamp":1777612370000},"page":"1776-1799","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":18,"title":["Perioperative management of patients taking sodium-glucose cotransporter 2 inhibitors: Society for Perioperative Assessment and Quality Improvement (SPAQI) multidisciplinary consensus statement"],"prefix":"10.1016","volume":"136","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3369-382X","authenticated-orcid":false,"given":"Adriana D.","family":"Oprea","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Basma","family":"Mohamed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2738-6682","authenticated-orcid":false,"given":"David L.","family":"Hepner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6398-6047","authenticated-orcid":false,"given":"Moises","family":"Auron","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7127-6966","authenticated-orcid":false,"given":"Deborah C.","family":"Richman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guillermo E.","family":"Umpierrez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2589-6993","authenticated-orcid":false,"given":"Daniel","family":"Edmonston","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2633-5450","authenticated-orcid":false,"given":"Costin","family":"Ionescu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7847-9777","authenticated-orcid":false,"given":"Mandeep","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7497-0614","authenticated-orcid":false,"given":"BobbieJean","family":"Sweitzer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bja.2026.02.031_bib1","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1007\/s11606-024-09073-2","article-title":"Euglycemic ketoacidosis associated with SGLT-2 inhibitors in non-diabetic patients-a narrative review","volume":"40","author":"Garg","year":"2024","journal-title":"J Gen Intern Med"},{"key":"10.1016\/j.bja.2026.02.031_bib2","doi-asserted-by":"crossref","DOI":"10.1136\/bmjdrc-2023-003666","article-title":"Euglycemic diabetic ketoacidosis in the era of SGLT-2 inhibitors","volume":"11","author":"Chow","year":"2023","journal-title":"BMJ Open Diabetes Res Care"},{"key":"10.1016\/j.bja.2026.02.031_bib3","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1213\/ANE.0000000000002377","article-title":"Perioperative considerations for the use of sodium-glucose Cotransporter-2 inhibitors in patients with type 2 diabetes","volume":"126","author":"Peacock","year":"2018","journal-title":"Anesth Analg"},{"issue":"Suppl. 1","key":"10.1016\/j.bja.2026.02.031_bib4","first-page":"S321","article-title":"Diabetes care in the hospital: standards of care in Diabetes-2025","volume":"48","year":"2025","journal-title":"Diabetes Care"},{"key":"10.1016\/j.bja.2026.02.031_bib5","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1111\/anae.16461","article-title":"The peri-operative implications of sodium-glucose co-transporter 2 inhibitors: a narrative review","volume":"80","author":"Stewart","year":"2025","journal-title":"Anaesthesia"},{"key":"10.1016\/j.bja.2026.02.031_bib6","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1001\/jamasurg.2025.0940","article-title":"Postoperative outcomes among sodium-glucose cotransporter 2 inhibitor users","volume":"160","author":"Tallarico","year":"2025","journal-title":"JAMA Surg"},{"key":"10.1016\/j.bja.2026.02.031_bib7","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/j.bja.2024.05.004","article-title":"Risk of perioperative discontinuation of SGLT2 inhibitors","volume":"133","author":"Oosterom-Eijmael","year":"2024","journal-title":"Br J Anaesth"},{"key":"10.1016\/j.bja.2026.02.031_bib8","doi-asserted-by":"crossref","first-page":"2071","DOI":"10.1111\/dom.14805","article-title":"Re-examining the widespread policy of stopping sodium-glucose cotransporter-2 inhibitors during acute illness: a perspective based on the updated evidence","volume":"24","author":"Khunti","year":"2022","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.bja.2026.02.031_bib9","doi-asserted-by":"crossref","first-page":"47","DOI":"10.3949\/ccjm.88a.20088","article-title":"The role of SGLT-2 inhibitors in managing type 2 diabetes","volume":"88","author":"Tsushima","year":"2021","journal-title":"Cleve Clin J Med"},{"key":"10.1016\/j.bja.2026.02.031_bib10","doi-asserted-by":"crossref","first-page":"273","DOI":"10.2337\/dci21-0050","article-title":"The brains behind SGLT2 inhibition","volume":"45","author":"Schl\u00f6gl","year":"2022","journal-title":"Diabetes Care"},{"key":"10.1016\/j.bja.2026.02.031_bib11","doi-asserted-by":"crossref","first-page":"1630","DOI":"10.1111\/obr.12755","article-title":"Weight loss associated with sodium-glucose cotransporter-2 inhibition: a review of evidence and underlying mechanisms","volume":"19","author":"Lee","year":"2018","journal-title":"Obes Rev"},{"key":"10.1016\/j.bja.2026.02.031_bib12","doi-asserted-by":"crossref","DOI":"10.2174\/1573399820666230525150437","article-title":"An update on the effect of sodium glucose cotransporter 2 inhibitors on non-alcoholic fatty liver disease: a systematic review of clinical trials","volume":"20","author":"Alfayez","year":"2024","journal-title":"Curr Diabetes Rev"},{"key":"10.1016\/j.bja.2026.02.031_bib13","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1056\/NEJMoa2024816","article-title":"Dapagliflozin in patients with chronic kidney disease","volume":"383","author":"Heerspink","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.bja.2026.02.031_bib14","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1056\/NEJMoa2204233","article-title":"Empagliflozin in patients with chronic kidney disease","volume":"388","author":"Herrington","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.bja.2026.02.031_bib15","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1056\/NEJMoa1811744","article-title":"Canagliflozin and renal outcomes in type 2 diabetes and nephropathy","volume":"380","author":"Perkovic","year":"2019","journal-title":"N Engl J Med"},{"issue":"Suppl. 1","key":"10.1016\/j.bja.2026.02.031_bib16","first-page":"S207","article-title":"Cardiovascular disease and risk management: standards of care in Diabetes-2025","volume":"48","year":"2025","journal-title":"Diabetes Care"},{"key":"10.1016\/j.bja.2026.02.031_bib17","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1172\/JCI72227","article-title":"Metabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patients","volume":"124","author":"Ferrannini","year":"2014","journal-title":"J Clin Invest"},{"key":"10.1016\/j.bja.2026.02.031_bib18","doi-asserted-by":"crossref","first-page":"771","DOI":"10.2337\/dc16-2724","article-title":"Renal handling of ketones in response to sodium-glucose cotransporter 2 inhibition in patients with type 2 diabetes","volume":"40","author":"Ferrannini","year":"2017","journal-title":"Diabetes Care"},{"key":"10.1016\/j.bja.2026.02.031_bib19","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1016\/j.ekir.2022.02.023","article-title":"The adaptive renal response for volume homeostasis during 2 weeks of dapagliflozin treatment in people with type 2 diabetes and preserved renal function on a sodium-controlled diet","volume":"7","author":"Scholtes","year":"2022","journal-title":"Kidney Int Rep"},{"key":"10.1016\/j.bja.2026.02.031_bib20","doi-asserted-by":"crossref","first-page":"440","DOI":"10.2337\/dc20-2604","article-title":"Natriuretic effect of two weeks of dapagliflozin treatment in patients with type 2 diabetes and preserved kidney function during standardized sodium intake: results of the DAPASALT trial","volume":"44","author":"Scholtes","year":"2021","journal-title":"Diabetes Care"},{"key":"10.1016\/j.bja.2026.02.031_bib21","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1016\/S2213-8587(24)00102-5","article-title":"Effect of SGLT2 inhibitors on heart failure outcomes and cardiovascular death across the cardiometabolic disease spectrum: a systematic review and meta-analysis","volume":"12","author":"Usman","year":"2024","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.bja.2026.02.031_bib22","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1016\/j.jacbts.2020.02.004","article-title":"Mechanisms of cardiovascular benefits of sodium glucose co-transporter 2 (SGLT2) inhibitors: A state-of-the-art review","volume":"5","author":"Lopaschuk","year":"2020","journal-title":"JACC Basic Transl Sci"},{"key":"10.1016\/j.bja.2026.02.031_bib23","doi-asserted-by":"crossref","first-page":"8786","DOI":"10.3390\/ijms22168786","article-title":"Effects of sodium-glucose co-transporter 2 inhibitors on vascular cell function and arterial remodeling","volume":"22","author":"Durante","year":"2021","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.bja.2026.02.031_bib24","doi-asserted-by":"crossref","first-page":"2134","DOI":"10.1007\/s00125-018-4678-z","article-title":"SGLT2 inhibitors: the future for treatment of type 2 diabetes mellitus and other chronic diseases","volume":"61","author":"Wanner","year":"2018","journal-title":"Diabetologia"},{"key":"10.1016\/j.bja.2026.02.031_bib25","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1111\/anae.16541","volume":"80","author":"El-Boghdadly","year":"2025","journal-title":"Anaesthesia"},{"key":"10.1016\/j.bja.2026.02.031_bib26","doi-asserted-by":"crossref","first-page":"264","DOI":"10.3390\/metabo14050264","article-title":"Ketoacidosis and SGLT2 inhibitors: A narrative review","volume":"14","author":"Morace","year":"2024","journal-title":"Metabolites"},{"key":"10.1016\/j.bja.2026.02.031_bib27","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.jcjd.2021.04.006","article-title":"Sodium-glucose Cotransporter-2 inhibitors and risk of diabetic ketoacidosis among adults with type 2 diabetes: a systematic review and meta-analysis","volume":"46","author":"Colacci","year":"2022","journal-title":"Can J Diabetes"},{"key":"10.1016\/j.bja.2026.02.031_bib28","doi-asserted-by":"crossref","first-page":"1661","DOI":"10.1002\/cpt.3615","article-title":"Sodium-glucose Cotransporter-2 inhibitors and diabetic-ketoacidosis in T2DM patients: an updated meta-analysis and a Mendelian randomization analysis","volume":"117","author":"Wang","year":"2025","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.bja.2026.02.031_bib29","doi-asserted-by":"crossref","first-page":"417","DOI":"10.7326\/M20-0289","article-title":"Sodium-glucose Cotransporter-2 inhibitors and the risk for diabetic ketoacidosis: A multicenter cohort study","volume":"173","author":"Douros","year":"2020","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.bja.2026.02.031_bib30","doi-asserted-by":"crossref","first-page":"2963","DOI":"10.1111\/dom.15193","article-title":"Safety of sodium-glucose cotransporter 2 inhibitors in elderly patients with type 2 diabetes: a meta-analysis of randomized controlled trials","volume":"25","author":"Rigato","year":"2023","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.bja.2026.02.031_bib31","doi-asserted-by":"crossref","first-page":"e123","DOI":"10.2337\/dc16-0885","article-title":"Effect of sodium-glucose cotransporter 2 inhibitors on diabetic ketoacidosis among patients with type 2 diabetes: a meta-analysis of randomized controlled trials","volume":"39","author":"Tang","year":"2016","journal-title":"Diabetes Care"},{"key":"10.1016\/j.bja.2026.02.031_bib32","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.1053\/j.jvca.2025.02.030","article-title":"Retrospective chart review of euglycemic diabetic ketoacidosis rates and outcomes postimplementation of sodium glucose cotransporter 2 inhibitor use stoppage 5 days before open heart surgery","volume":"39","author":"Auerbach","year":"2025","journal-title":"J Cardiothorac Vasc Anesth"},{"key":"10.1016\/j.bja.2026.02.031_bib33","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1053\/j.jvca.2023.01.041","article-title":"Postcardiac surgery euglycemic diabetic ketoacidosis in patients on sodium-glucose cotransporter 2 inhibitors","volume":"37","author":"Auerbach","year":"2023","journal-title":"J Cardiothorac Vasc Anesth"},{"key":"10.1016\/j.bja.2026.02.031_bib34","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1097\/EJA.0000000000002090","article-title":"Metabolic acidosis in patients with diabetes 2 undergoing cardiac surgery: the impact of SGLT2 inhibitor use: a retrospective cohort study","volume":"42","author":"Brekke","year":"2025","journal-title":"Eur J Anaesthesiol"},{"key":"10.1016\/j.bja.2026.02.031_bib35","doi-asserted-by":"crossref","first-page":"8087","DOI":"10.1038\/s41598-024-58853-7","article-title":"Missed postoperative metabolic acidosis associated with sodium-glucose transporter 2 inhibitors in cardiac surgery patients: a retrospective analysis","volume":"14","author":"Kim","year":"2024","journal-title":"Sci Rep"},{"key":"10.1016\/j.bja.2026.02.031_bib36","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1111\/imj.15772","article-title":"Sodium-glucose cotransport-2 inhibitor induced ketoacidosis following coronary artery bypass surgery: implications for management","volume":"52","author":"McCann","year":"2022","journal-title":"Intern Med J"},{"key":"10.1016\/j.bja.2026.02.031_bib37","doi-asserted-by":"crossref","first-page":"460","DOI":"10.4103\/aca.aca_47_21","article-title":"A retrospective analysis of the incidence, outcome and factors associated with the occurrence of euglycemic ketoacidosis in diabetic patients on sodium glucose co-transporter - 2 inhibitors undergoing cardiac surgery","volume":"25","author":"Murugesan","year":"2022","journal-title":"Ann Card Anaesth"},{"key":"10.1016\/j.bja.2026.02.031_bib38","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1213\/ANE.0000000000007705","article-title":"Impact of sodium-glucose Cotransporter-2 inhibitors on cardiovascular outcomes after cardiac surgery: a pilot study","volume":"142","author":"Labaste","year":"2025","journal-title":"Anesth Analg"},{"key":"10.1016\/j.bja.2026.02.031_bib39","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1186\/s12933-025-02773-x","article-title":"Impact of SGLT2-inhibitors on acute kidney injury in diabetic patients with severe aortic stenosis undergoing transcatheter aortic valve implantation (TAVI)","volume":"24","author":"Paolisso","year":"2025","journal-title":"Cardiovasc Diabetol"},{"key":"10.1016\/j.bja.2026.02.031_bib40","doi-asserted-by":"crossref","first-page":"988","DOI":"10.2337\/dc24-2807","article-title":"Empagliflozin in patients with type 2 diabetes undergoing on-pump CABG: the POST-CABGDM randomized clinical trial","volume":"48","author":"Pitta","year":"2025","journal-title":"Diabetes Care"},{"key":"10.1016\/j.bja.2026.02.031_bib41","doi-asserted-by":"crossref","first-page":"3077","DOI":"10.1210\/jc.2019-00139","article-title":"SGLT2 inhibitors increase the risk of diabetic ketoacidosis developing in the community and during hospital admission","volume":"104","author":"Hamblin","year":"2019","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.bja.2026.02.031_bib42","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1007\/s40264-022-01247-3","article-title":"A population-based study of SGLT2 inhibitor-associated postoperative diabetic ketoacidosis in patients with type 2 diabetes","volume":"46","author":"Lui","year":"2023","journal-title":"Drug Saf"},{"key":"10.1016\/j.bja.2026.02.031_bib43","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1007\/s00540-024-03335-3","article-title":"Incidence of sodium-glucose cotransporter-2 inhibitor-associated perioperative ketoacidosis in surgical patients: a prospective cohort study","volume":"38","author":"Seki","year":"2024","journal-title":"J Anesth"},{"key":"10.1016\/j.bja.2026.02.031_bib44","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1016\/j.bja.2023.06.063","article-title":"Dose-dependent relationship between SGLT2 inhibitor hold time and risk for postoperative anion gap acidosis: a single-centre retrospective analysis","volume":"131","author":"Steinhorn","year":"2023","journal-title":"Br J Anaesth"},{"key":"10.1016\/j.bja.2026.02.031_bib45","doi-asserted-by":"crossref","first-page":"3181","DOI":"10.1016\/j.ekir.2025.06.036","article-title":"The protective effects of SGLT-2 inhibitors against postoperative acute kidney injury in type 2 diabetes","volume":"10","author":"Song","year":"2025","journal-title":"Kidney Int Rep"},{"key":"10.1016\/j.bja.2026.02.031_bib46","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1111\/anae.70024","article-title":"Association between pre-operative sodium-glucose cotransporter-2 inhibitor use and postoperative outcomes: a propensity score-matched analysis of the TriNetX database","volume":"81","author":"Wu","year":"2025","journal-title":"Anaesthesia"},{"key":"10.1016\/j.bja.2026.02.031_bib47","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1186\/s40780-025-00487-6","article-title":"Factors and preventive strategies for perioperative euglycemic diabetic ketoacidosis in patients with type 2 diabetes receiving sodium-glucose cotransporter 2 inhibitors: a retrospective study","volume":"11","author":"Takemura","year":"2025","journal-title":"J Pharm Health Care Sci"},{"key":"10.1016\/j.bja.2026.02.031_bib48","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1001\/jamasurg.2024.7082","article-title":"Preoperative SGLT2 inhibitor use and postoperative diabetic ketoacidosis","volume":"160","author":"Dixit","year":"2025","journal-title":"JAMA Surg"},{"key":"10.1016\/j.bja.2026.02.031_bib49","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1016\/j.bja.2024.12.024","article-title":"Preoperative SGLT-2 inhibitor use and risk of adverse postoperative events: a single-centre retrospective observational study","volume":"134","author":"Tenge","year":"2025","journal-title":"Br J Anaesth"},{"key":"10.1016\/j.bja.2026.02.031_bib50","doi-asserted-by":"crossref","first-page":"3599","DOI":"10.1007\/s11695-025-08002-4","article-title":"Impact of SGLT2 inhibitors use on risk of postoperative acute kidney injury following metabolic and bariatric surgery: a retrospective study","volume":"35","author":"Chen","year":"2025","journal-title":"Obes Surg"},{"key":"10.1016\/j.bja.2026.02.031_bib51","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1016\/j.eprac.2024.04.012","article-title":"Prolonged diabetic ketoacidosis associated with sodium-glucose Cotransporter-2 inhibitors: a review of postmarketing cases","volume":"30","author":"Woronow","year":"2024","journal-title":"Endocr Pract"},{"key":"10.1016\/j.bja.2026.02.031_bib52","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1080\/14740338.2023.2275704","article-title":"The risk factors of diabetic ketosis and diabetic ketoacidosis among patients with type 2 diabetes mellitus treated with SGLT2 inhibitors: a retrospective study","volume":"23","author":"Zhao","year":"2024","journal-title":"Expert Opin Drug Saf"},{"key":"10.1016\/j.bja.2026.02.031_bib53","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1186\/s12902-022-01126-z","article-title":"The effect of preoperative sodium-glucose cotransporter 2 inhibitors on the incidence of perioperative metabolic acidosis: a retrospective cohort study","volume":"22","author":"Iwasaki","year":"2022","journal-title":"BMC Endocr Disord"},{"key":"10.1016\/j.bja.2026.02.031_bib54","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1016\/j.eprac.2022.06.006","article-title":"Inpatient perioperative euglycemic diabetic ketoacidosis due to sodium-glucose Cotransporter-2 inhibitors - lessons from a case series and strategies to decrease incidence","volume":"28","author":"Mehta","year":"2022","journal-title":"Endocr Pract"},{"key":"10.1016\/j.bja.2026.02.031_bib55","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1111\/imj.15366","article-title":"An audit of the effect of SGLT2 inhibitor cessation in a pre-admission clinic before and after Australian Diabetes Society guidelines","volume":"51","author":"Fookeerah","year":"2021","journal-title":"Intern Med J"},{"key":"10.1016\/j.bja.2026.02.031_bib56","doi-asserted-by":"crossref","first-page":"e5","DOI":"10.1016\/j.bja.2021.03.023","article-title":"Metabolic outcomes in patients with diabetes mellitus administered SGLT2 inhibitors immediately before emergency or elective surgery: single centre experience and recommendations","volume":"127","author":"Wang","year":"2021","journal-title":"Br J Anaesth"},{"key":"10.1016\/j.bja.2026.02.031_bib57","first-page":"391","article-title":"Management of sodium-glucose cotransporter 2 inhibitors during the perioperative period: a retrospective comparative study","volume":"31","author":"Ge","year":"2021","journal-title":"J Perioper Pract"},{"key":"10.1016\/j.bja.2026.02.031_bib84","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1093\/bjs\/znad044","article-title":"Sodium-glucose cotransporter 2 inhibitor-induced postoperative euglycaemic diabetic ketoacidosis after pancreatectomy","volume":"110","author":"Armstrong","year":"2023","journal-title":"Br J Surg"},{"key":"10.1016\/j.bja.2026.02.031_bib59","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1056\/NEJMoa1911303","article-title":"Dapagliflozin in patients with heart failure and reduced ejection fraction","volume":"381","author":"McMurray","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.bja.2026.02.031_bib60","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1056\/NEJMoa2107038","article-title":"Empagliflozin in heart failure with a preserved ejection fraction","volume":"385","author":"Anker","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.bja.2026.02.031_bib61","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1056\/NEJMoa2022190","article-title":"Cardiovascular and renal outcomes with empagliflozin in heart failure","volume":"383","author":"Packer","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.bja.2026.02.031_bib62","doi-asserted-by":"crossref","first-page":"2601","DOI":"10.1007\/s11606-020-06561-z","article-title":"Identifying risk factors for diabetic ketoacidosis associated with SGLT2 inhibitors: a nationwide cohort study in the USA","volume":"36","author":"Fralick","year":"2021","journal-title":"J Gen Intern Med"},{"key":"10.1016\/j.bja.2026.02.031_bib63","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1016\/j.jdiacomp.2016.11.004","article-title":"Hyperglycemic, high anion-gap metabolic acidosis in patients receiving SGLT-2 inhibitors for diabetes management","volume":"31","author":"Kum-Nji","year":"2017","journal-title":"J Diabetes Complications"},{"key":"10.1016\/j.bja.2026.02.031_bib64","doi-asserted-by":"crossref","DOI":"10.3389\/fsurg.2022.828649","article-title":"New diabetic medication sodium-glucose Cotransporter-2 inhibitors can induce euglycemic ketoacidosis and mimic surgical diseases: a case report and review of literature","volume":"9","author":"Kietaibl","year":"2022","journal-title":"Front Surg"},{"key":"10.1016\/j.bja.2026.02.031_bib65","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1002\/pdi.2455","article-title":"A case series of diabetic ketoacidosis associated with SGLT2 inhibitors","volume":"40","author":"Zac-Varghese","year":"2023","journal-title":"Pract Diabetes"},{"key":"10.1016\/j.bja.2026.02.031_bib58","doi-asserted-by":"crossref","DOI":"10.1177\/11795514231153717","article-title":"Clinical characteristics and outcomes of diabetic ketoacidosis in patients with type 2 diabetes using SGLT2 inhibitors","volume":"16","author":"Almazrouei","year":"2023","journal-title":"Clin Med Insights Endocrinol Diabetes"},{"key":"10.1016\/j.bja.2026.02.031_bib66","doi-asserted-by":"crossref","first-page":"361","DOI":"10.4082\/kjfm.22.0003","article-title":"Dietary changes leading to euglycemic diabetic ketoacidosis in sodium-glucose Cotransporter-2 inhibitor users: A challenge for primary care physicians?","volume":"43","author":"Somagutta","year":"2022","journal-title":"Korean J Fam Med"},{"key":"10.1016\/j.bja.2026.02.031_bib67","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2025-098758","article-title":"Euglycaemic diabetic ketoacidosis and its risk factors in patients undergoing coronary artery bypass grafting surgery: a single-centre nested case-control study in China","volume":"15","author":"Hu","year":"2025","journal-title":"BMJ Open"},{"key":"10.1016\/j.bja.2026.02.031_bib68","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.bja.2019.03.028","article-title":"Perioperative diabetic ketoacidosis associated with sodium-glucose co-transporter-2 inhibitors: a systematic review","volume":"123","author":"Thiruvenkatarajan","year":"2019","journal-title":"Br J Anaesth"},{"key":"10.1016\/j.bja.2026.02.031_bib69","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1007\/s00540-023-03174-8","article-title":"Sodium-glucose cotransporter 2 inhibitor-associated perioperative ketoacidosis: a systematic review of case reports","volume":"37","author":"Seki","year":"2023","journal-title":"J Anesth"},{"key":"10.1016\/j.bja.2026.02.031_bib70","unstructured":"Hwang SM, Abcejo AS, Jacob AK, et al. Editorial: Euglycemic ketoacidosis concerns in perioperative use of SGLT2 inhibitors:re-examining current recommendations. APSF Newsletter 2025;13\u20135. https:\/\/www.apsf.org\/wp-content\/uploads\/newsletters\/2025\/4001\/APSF4001-a05-Euglycemic-Ketoacidosis.pdf (Accessed April 21, 2026)."},{"key":"10.1016\/j.bja.2026.02.031_bib71","doi-asserted-by":"crossref","first-page":"e351","DOI":"10.1161\/CIR.0000000000001285","article-title":"AHA\/ACC\/ACS\/ASNC\/HRS\/SCA\/SCCT\/SCMR\/SVM guideline for perioperative cardiovascular management for noncardiac surgery: a report of the American College of Cardiology\/American Heart Association joint committee on clinical practice guidelines","volume":"150","author":"Thompson","year":"2024","journal-title":"Circulation"},{"key":"10.1016\/j.bja.2026.02.031_bib72","unstructured":"Australian and New Zealand College of Anaesthetists. Periprocedural diabetic ketoacidosis (DKA) with SGLT2 inhibitor use in people with diabetes, https:\/\/www.diabetessociety.com.au\/downloads\/20220726%20ADS%20ADEA%20ANZCA%20NZSSD_DKA_SGLT2i_Alert_Ver%20July%202022.pdf; (accessed November 25, 2025)."},{"key":"10.1016\/j.bja.2026.02.031_bib73","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1080\/03007995.2025.2458538","article-title":"Perioperative and periprocedural management of GLP-1 receptor-based agonists and SGLT2 inhibitors: narrative review and the STOP-GAP and STOP DKA-2 algorithms","volume":"41","author":"Goldenberg","year":"2025","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.bja.2026.02.031_bib74","doi-asserted-by":"crossref","first-page":"116","DOI":"10.5662\/wjm.v11.i4.116","article-title":"Delphi methodology in healthcare research: how to decide its appropriateness","volume":"11","author":"Nasa","year":"2021","journal-title":"World J Methodol"},{"key":"10.1016\/j.bja.2026.02.031_bib75","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1007\/s12020-022-03290-7","article-title":"Safety of sodium-glucose cotransporter 2 inhibitors (SGLT2i) during the month of Ramadan in patients with type 2 diabetes mellitus in Pakistani population-an observational study from a tertiary care center in Karachi","volume":"80","author":"Sheikh","year":"2023","journal-title":"Endocrine"},{"key":"10.1016\/j.bja.2026.02.031_bib76","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1111\/jdi.13741","article-title":"Effect of Ramadan fasting in patients with type 2 diabetes mellitus treated with sodium-glucose cotransporter 2 inhibitors: A systematic review and meta-analysis","volume":"13","author":"Gad","year":"2022","journal-title":"J Diabetes Investig"},{"key":"10.1016\/j.bja.2026.02.031_bib77","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1097\/ALN.0000000000004381","volume":"138","author":"Joshi","year":"2023","journal-title":"Anesthesiology"},{"key":"10.1016\/j.bja.2026.02.031_bib79","doi-asserted-by":"crossref","DOI":"10.1016\/j.deman.2023.100138","article-title":"Ketosis in patients undergoing colonoscopy \u2013 more common than we think","volume":"11","author":"Sharma","year":"2023","journal-title":"Diabetes Epidemiol Manag"},{"key":"10.1016\/j.bja.2026.02.031_bib80","doi-asserted-by":"crossref","first-page":"e91","DOI":"10.2337\/dc21-1870","article-title":"Sodium-glucose cotransporter 2 inhibitor-linked pericolonoscopy hyperketonemia: A retrospective study","volume":"45","author":"Thiruvenkatarajan","year":"2022","journal-title":"Diabetes Care"},{"key":"10.1016\/j.bja.2026.02.031_bib81","doi-asserted-by":"crossref","first-page":"e181","DOI":"10.2337\/dc20-1244","article-title":"Periprocedural euglycemic diabetic ketoacidosis associated with sodium-glucose cotransporter 2 inhibitor therapy during colonoscopy","volume":"43","author":"Meyer","year":"2020","journal-title":"Diabetes Care"},{"key":"10.1016\/j.bja.2026.02.031_bib78","doi-asserted-by":"crossref","first-page":"e124","DOI":"10.2337\/dc21-0256","article-title":"Capillary ketone concentrations at the time of colonoscopy: A cross-sectional study with implications for SGLT2 inhibitor-treated Type 2 diabetes","volume":"44","author":"Hamblin","year":"2021","journal-title":"Diabetes Care"},{"key":"10.1016\/j.bja.2026.02.031_bib82","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1111\/cen.14621","article-title":"Body mass index is inversely associated with capillary ketones at the time of colonoscopy: implications for SGLT2i use","volume":"96","author":"Hamblin","year":"2022","journal-title":"Clin Endocrinol (Oxf)"},{"key":"10.1016\/j.bja.2026.02.031_bib83","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1111\/cen.14707","article-title":"Letter to the editor: response to Hamblin et al. body mass index is inversely associated with capillary ketones at the time of colonoscopy: implications for SGLT2i use","volume":"98","author":"Umapathysivam","year":"2023","journal-title":"Clin Endocrinol (Oxf)"},{"key":"10.1016\/j.bja.2026.02.031_bib85","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1007\/s00125-022-05815-1","article-title":"Ketones: the double-edged sword of SGLT2 inhibitors?","volume":"66","author":"Lupsa","year":"2023","journal-title":"Diabetologia"},{"key":"10.1016\/j.bja.2026.02.031_bib86","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1016\/j.bja.2024.05.022","article-title":"Ketonaemia during cardiopulmonary bypass surgery: a prospective observational study","volume":"133","author":"Snel","year":"2024","journal-title":"Br J Anaesth"},{"key":"10.1016\/j.bja.2026.02.031_bib87","doi-asserted-by":"crossref","DOI":"10.1016\/j.jclinane.2025.111811","article-title":"The effects of sodium-glucose transporter 2 inhibition on cardiac surgery-associated acute kidney injury: an open-label randomized pilot study","volume":"103","author":"Snel","year":"2025","journal-title":"J Clin Anesth"},{"key":"10.1016\/j.bja.2026.02.031_bib88","article-title":"Sodium-glucose co-transporter 2 inhibitor-associated euglycemic diabetic ketoacidosis after bariatric surgery: a case and literature review","volume":"13","author":"Kapila","year":"2021","journal-title":"Cureus"},{"key":"10.1016\/j.bja.2026.02.031_bib89","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1213\/XAA.0000000000000734","article-title":"When guidelines fail: euglycemic diabetic ketoacidosis after bariatric surgery in a patient taking a sodium-glucose Cotransporter-2 inhibitor: a case report","volume":"11","author":"Lane","year":"2018","journal-title":"A A Pract"},{"key":"10.1016\/j.bja.2026.02.031_bib90","article-title":"A case of diabetic ketoacidosis in a patient on an SGLT2 inhibitor and a ketogenic diet: a critical trio not to be missed","volume":"2020","author":"Steinmetz-Wood","year":"2020","journal-title":"Case Rep Endocrinol"},{"key":"10.1016\/j.bja.2026.02.031_bib91","article-title":"Sodium-glucose linked transporter inhibitors as a cause of euglycemic diabetic ketoacidosis on a background of starvation","volume":"12","author":"Tauseef","year":"2020","journal-title":"Cureus"},{"key":"10.1016\/j.bja.2026.02.031_bib92","doi-asserted-by":"crossref","DOI":"10.1002\/ams2.480","article-title":"Euglycemic diabetic ketoacidosis due to a strict low-carbohydrate diet during treatment with sodium-glucose cotransporter 2 inhibitors","volume":"7","author":"Fukuyama","year":"2020","journal-title":"Acute Med Surg"},{"key":"10.1016\/j.bja.2026.02.031_bib93","doi-asserted-by":"crossref","first-page":"e11","DOI":"10.1016\/j.soard.2015.08.502","article-title":"Normoglycemic ketoacidosis in a postoperative gastric bypass patient taking canagliflozin","volume":"12","author":"Bonanni","year":"2016","journal-title":"Surg Obes Relat Dis"},{"key":"10.1016\/j.bja.2026.02.031_bib94","article-title":"SGLT-2 inhibitors-a culprit of diabetic ketoacidosis postbariatric surgery","volume":"2020","author":"Iqbal","year":"2020","journal-title":"Case Rep Crit Care"},{"key":"10.1016\/j.bja.2026.02.031_bib95","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1016\/j.jcjd.2017.05.004","article-title":"Insights into the recognition and management of SGLT2-inhibitor-associated ketoacidosis: it's not just euglycemic diabetic ketoacidosis","volume":"41","author":"Dizon","year":"2017","journal-title":"Can J Diabetes"},{"key":"10.1016\/j.bja.2026.02.031_bib96","doi-asserted-by":"crossref","first-page":"1997","DOI":"10.1177\/0003134820940286","article-title":"Euglycemic diabetic ketoacidosis associated with use of SGLT2 inhibitor after laparoscopic Roux-en-Y gastric bypass","volume":"87","author":"Yared","year":"2021","journal-title":"Am Surg"},{"key":"10.1016\/j.bja.2026.02.031_bib97","doi-asserted-by":"crossref","first-page":"3848","DOI":"10.1007\/s11695-021-05391-0","article-title":"Two cases of euglycemic diabetic ketoacidosis after bariatric surgery associated with sodium-glucose cotransporter-2 inhibitor use","volume":"31","author":"Amianda","year":"2021","journal-title":"Obes Surg"},{"key":"10.1016\/j.bja.2026.02.031_bib98","doi-asserted-by":"crossref","first-page":"812","DOI":"10.4103\/ija.ija_448_22","article-title":"Euglycaemic diabetic ketoacidosis after bariatric surgery: A Near-Miss","volume":"66","author":"Rathi","year":"2022","journal-title":"Indian J Anaesth"},{"key":"10.1016\/j.bja.2026.02.031_bib99","doi-asserted-by":"crossref","DOI":"10.1136\/bcr-2017-221527","article-title":"Euglycaemic diabetic ketoacidosis in bariatric surgery patients with type 2 diabetes taking canagliflozin","volume":"2018","author":"van Niekerk","year":"2018","journal-title":"BMJ Case Rep"},{"key":"10.1016\/j.bja.2026.02.031_bib100","doi-asserted-by":"crossref","DOI":"10.1016\/j.deman.2024.100201","article-title":"The efficacy of a 24-hour preoperative pause for SGLT2-inhibitors in type II diabetes patients undergoing bariatric surgery to mitigate euglycemic diabetic ketoacidosis","volume":"14","author":"Younes","year":"2024","journal-title":"Diabetes Epidemiol Manag"},{"key":"10.1016\/j.bja.2026.02.031_bib101","article-title":"Post-operative euglycemic diabetic ketoacidosis in a patient with SGLT-2 inhibitor use and recent sleeve gastrectomy","volume":"13","author":"Smith","year":"2021","journal-title":"Cureus"},{"key":"10.1016\/j.bja.2026.02.031_bib102","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1038\/s41387-023-00246-2","article-title":"Adherence to ketogenic diet in lifestyle interventions in adults with overweight or obesity and type 2 diabetes: a scoping review","volume":"13","author":"Li","year":"2023","journal-title":"Nutr Diabetes"},{"key":"10.1016\/j.bja.2026.02.031_bib103","first-page":"17","article-title":"Euglycemic diabetic ketoacidosis caused by SGLT2 inhibitors and a ketogenic diet: A case series and review of literature","volume":"7","author":"Mistry","year":"2021","journal-title":"AACE Clin Case Rep"},{"key":"10.1016\/j.bja.2026.02.031_bib104","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1111\/dom.16252","article-title":"Illnesses associated with ketosis including diabetic ketoacidosis during very low carbohydrate and ketogenic diets","volume":"27","author":"Roberts","year":"2025","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.bja.2026.02.031_bib105","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1111\/dom.12848","article-title":"Sodium-glucose co-transporter-2 inhibitor use and dietary carbohydrate intake in Japanese individuals with type 2 diabetes: A randomized, open-label, 3-arm parallel comparative, exploratory study","volume":"19","author":"Yabe","year":"2017","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.bja.2026.02.031_bib106","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1111\/dom.12881","article-title":"Determinants of the increase in ketone concentration during SGLT2 inhibition in NGT, IFG and T2DM patients","volume":"19","author":"Al Jobori","year":"2017","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.bja.2026.02.031_bib107","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCHEARTFAILURE.118.004953","article-title":"Increased cardiac uptake of ketone bodies and free fatty acids in human heart failure and hypertrophic left ventricular remodeling","volume":"11","author":"Voros","year":"2018","journal-title":"Circ Heart Fail"},{"key":"10.1016\/j.bja.2026.02.031_bib108","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1016\/S0140-6736(20)31824-9","article-title":"SGLT2 inhibitors in patients with heart failure with reduced ejection fraction: a meta-analysis of the EMPEROR-Reduced and DAPA-HF trials","volume":"396","author":"Zannad","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.bja.2026.02.031_bib109","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1016\/j.mayocp.2023.04.003","article-title":"Alcoholic ketoacidosis manifesting with hypoglycemia exacerbated by an SGLT2 inhibitor in a nondiabetic patient","volume":"98","author":"Iesaka","year":"2023","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.bja.2026.02.031_bib110","doi-asserted-by":"crossref","first-page":"140","DOI":"10.2337\/dc23-1163","article-title":"Euglycemic ketoacidosis in two patients without diabetes after introduction of sodium-glucose cotransporter 2 inhibitor for heart failure with reduced ejection fraction","volume":"47","author":"Umapathysivam","year":"2024","journal-title":"Diabetes Care"},{"key":"10.1016\/j.bja.2026.02.031_bib111","doi-asserted-by":"crossref","first-page":"e4","DOI":"10.2337\/dc23-1903","article-title":"SGLT2 Inhibitor-induced ketoacidosis in a patient without diabetes","volume":"47","author":"Hayes","year":"2024","journal-title":"Diabetes Care"},{"key":"10.1016\/j.bja.2026.02.031_bib112","doi-asserted-by":"crossref","DOI":"10.12659\/AJCR.943945","article-title":"Euglycemic ketoacidosis in a patient without diabetes taking sodium-glucose cotransporter 2 inhibitors for heart failure","volume":"25","author":"Miyazaki","year":"2024","journal-title":"Am J Case Rep"},{"key":"10.1016\/j.bja.2026.02.031_bib113","doi-asserted-by":"crossref","DOI":"10.4081\/itjm.2024.1716","article-title":"Sodium-glucose co-transporter-2 inhibitor-associated non-diabetic ketoacidosis: a case report","volume":"18","author":"Trapanese","year":"2024","journal-title":"Italian Journal of Medicine"},{"key":"10.1016\/j.bja.2026.02.031_bib114","doi-asserted-by":"crossref","first-page":"2800","DOI":"10.1016\/S0735-1097(24)04790-9","article-title":"Pulmonary artery monitoring device detects empagliflozin-induced ketoacidosis in a non-diabetic patient","volume":"83","author":"Bejjani","year":"2024","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.bja.2026.02.031_bib115","doi-asserted-by":"crossref","first-page":"2636","DOI":"10.1016\/j.transproceed.2021.08.017","article-title":"Sodium-glucose Cotransporter-2 inhibitor-associated euglycemic diabetic ketoacidosis after orthotopic heart transplant in a prediabetic patient: a case report","volume":"53","author":"Cha","year":"2021","journal-title":"Transplant Proc"},{"key":"10.1016\/j.bja.2026.02.031_bib116","article-title":"Postoperative ketoacidosis with hypoglycemia in a nondiabetic patient taking dapagliflozin for heart failure: A case report","volume":"16","author":"Seki","year":"2022","journal-title":"A A Pract"},{"key":"10.1016\/j.bja.2026.02.031_bib117","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1016\/j.bja.2023.11.015","article-title":"Sodium-glucose cotransporter-2 inhibitors in non-diabetic patients: is there a perioperative risk of euglycaemic ketoacidosis","volume":"132","author":"Ruste","year":"2024","journal-title":"Br J Anaesth"},{"key":"10.1016\/j.bja.2026.02.031_bib118","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1186\/s13741-025-00548-2","article-title":"A case of perioperative euglycemic ketoacidosis in a patient without diabetes: are current guidelines enough?","volume":"14","author":"Hoque","year":"2025","journal-title":"Perioper Med (Lond)"},{"key":"10.1016\/j.bja.2026.02.031_bib119","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1016\/j.cardfail.2025.01.028","article-title":"Therapeutic ketosis for heart failure: A state-of-the-art review","volume":"31","author":"Kodur","year":"2025","journal-title":"J Card Fail"},{"key":"10.1016\/j.bja.2026.02.031_bib120","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1016\/j.xkme.2019.12.006","article-title":"SGLT. SGLT2 Inhibitor-induced euglycemic diabetic ketoacidosis: a case report","volume":"2","author":"Wang","year":"2020","journal-title":"Kidney Med"},{"key":"10.1016\/j.bja.2026.02.031_bib121","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1007\/s12055-021-01227-9","article-title":"Insulin and glucose infusion could prevent euglycemic diabetic ketoacidosis associated with sodium-glucose cotransporter 2 inhibitors","volume":"38","author":"Ito","year":"2022","journal-title":"Indian J Thorac Cardiovasc Surg"},{"key":"10.1016\/j.bja.2026.02.031_bib122","article-title":"Risk of euglycemic diabetic ketoacidosis can persist after discontinuation of sodium-glucose Cotransporter-2 inhibitors","volume":"3","author":"Bobba","year":"2025","journal-title":"JCEM Case Rep"},{"key":"10.1016\/j.bja.2026.02.031_bib123","doi-asserted-by":"crossref","first-page":"267","DOI":"10.2337\/dc21-2279","article-title":"Controversies around the measurement of blood ketones to diagnose and manage diabetic ketoacidosis","volume":"45","author":"Kilpatrick","year":"2022","journal-title":"Diabetes Care"},{"key":"10.1016\/j.bja.2026.02.031_bib124","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1900\/RDS.2016.13.217","article-title":"Blood ketones: measurement, interpretation, limitations, and utility in the management of diabetic ketoacidosis","volume":"13","author":"Dhatariya","year":"2016","journal-title":"Rev Diabet Stud"},{"key":"10.1016\/j.bja.2026.02.031_bib125","doi-asserted-by":"crossref","first-page":"e263","DOI":"10.1016\/j.jacc.2021.12.012","article-title":"AHA\/ACC\/HFSA guideline for the management of heart failure: a report of the American College of Cardiology\/American Heart Association joint committee on clinical practice guidelines","volume":"79","author":"Heidenreich","year":"2022","journal-title":"J Am Coll Cardiol"}],"container-title":["British Journal of Anaesthesia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0007091226001443?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0007091226001443?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,22]],"date-time":"2026-05-22T20:53:34Z","timestamp":1779483214000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0007091226001443"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":125,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["S0007091226001443"],"URL":"https:\/\/doi.org\/10.1016\/j.bja.2026.02.031","relation":{},"ISSN":["0007-0912"],"issn-type":[{"value":"0007-0912","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Perioperative management of patients taking sodium-glucose cotransporter 2 inhibitors: Society for Perioperative Assessment and Quality Improvement (SPAQI) multidisciplinary consensus statement","name":"articletitle","label":"Article Title"},{"value":"British Journal of Anaesthesia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bja.2026.02.031","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 British Journal of Anaesthesia. Published by Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}